HAVCR2 and plasma cell myeloma: Transduction and expansion of CAR T cells in the presence of PI3K inhibitors (e.g., Idelalisib or bb007) has been shown to enrich for less-differentiated CAR T cell phenotypes, reduce the expression of exhaustion markers such as PD-1 and TIM-3, enhance in vivo persistence, and improve antitumor efficacy in preclinical models of leukemia and multiple myeloma [78].